Atlas of Psychiatric Pharmacotherapy (Reprint)

Atlas of Psychiatric Pharmacotherapy (Reprint)

  • ただいまウェブストアではご注文を受け付けておりません。 ⇒古書を探す
  • 製本 Paperback:紙装版/ペーパーバック版/ページ数 235 p
  • 言語 ENG,ENG
  • 商品コード 9781853179341
  • DDC分類 615

基本説明

'This is a very useful resource...' Doody's Health Sciences Book Review Journal, 2000.

Table of Contents

Introduction                                       ix
Section A Basic principles of psychiatric 1 (100)
pharmacotherapy
Basic aspects related to drug action 2 (24)
Principles of drug action -- presynaptic 2 (2)
nerve
Control and modulation of
neurotransmitter release
Principles of drug action -- postsynaptic 4 (2)
nerve
Postsynaptic interactions and consequent
intracellular changes
Signal transduction (I) 6 (1)
Receptor Gs-protein interactions and
activation of the second-messenger system
Signal transduction (II) 7 (1)
Receptor Gp-protein interactions and
activation of the second-messenger system
Activation of receptors coupled to 8 (2)
G-proteins, ion channels or other
intracellular components
Cellular mediators and consequent changes
in second-messenger or other
intracellular compounds
Signal transduction (III) 10 (1)
Second messenger-protein kinases
interactions and consequent activation of
third messengers
Gene expression 11 (1)
Transcription protein synthesis and
consequent cellular changes
Neurotransmitters (synthesis and 12 (2)
degradation)
Biogenic amines: NE. DA. 5-HT. ACh.
epinephrine, histamine
Neurotransmitters 14 (1)
Glutamate: excitatory
Neurotransmitters 15 (1)
γ-Aminobutyric acid (GABA):
inhibitory
Vesicular monoamine transporter 16 (2)
Vesicular monoamine transporter type 2
(VMAT2)
Receptor/transporter-mediated reactions 18 (1)
Assumed side effects
Receptor-mediated psychiatric symptoms 19 (1)
Assumed roles specific receptors in major
psychiatric syndromes
Various receptor subtypes 20 (1)
Comparative distribution at different
brain regions
Specific ligands for various receptor 21 (1)
subtypes
Drug pharmacokinetics 22 (2)
Principles and major agents affecting the
hepatic microsomal enzymes
The P450 microsomal enzymes (I) 24 (1)
Various psychotropic substrates of the
P450 enzymes
The P450 microsomal enzymes (II) 25 (1)
Psychotropic drugs or compounds known to
inhibit or stimulate specific P450
isoenzymes
Antidepressants and mood stabilizers 26 (22)
Antidepressant drugs -- supposed mechanism 28 (1)
of action (I)
Euthymic state: no treatment
Antidepressant drugs -- supposed mechanism 28 (2)
of action (II)
Depressive state: no treatment
Antidepressant drugs -- supposed mechanism 30 (2)
of action (III)
Resolving depressive state: TCAs, TeCAs
and SSRIs treatment
Antidepressant drugs -- supposed mechanism 32 (2)
of action (IV)
Resolving depressive state; SNRIs and
atypical antidepressants treatment
Antidepressant drugs -- supposed mechanism 34 (2)
of action (V)
Resolving depressive state; MAOIs and
RIMAs treatment
Mood stabilizers -- lithium 36 (2)
Supposed mechanism of action
Mood stabilizers -- carbamazepine 38 (1)
Supposed mechanism of action
Mood stabilizers -- valproate 39 (1)
Supposed mechanism of action
Antimanic treatments 40 (2)
Supposed mechanism of action
Antidepressant drugs 42 (1)
Comparative affinitiy for different
receptors/transporters
Antidepressant drugs 43 (1)
Subclasses according to presumed mode of
therapeutic action
Antidepressant drugs 44 (1)
Comparative side effect profile
Monoamine oxidase inhibitors 45 (1)
Comparative side effect profile
Mood stabilizers 46 (2)
Comparative side effect profile
Antipsychotics 48 (10)
Antipsychotic drugs -- supposed mechanism 48 (2)
of action (I)
Schizophreniform psychosis; no treatment
Antipsychotic drugs -- supposed mechanism 50 (2)
of action (II)
Schizophreniform psychosis; treatment
with typical antipsychotic drugs
Antipsychotic drugs -- supposed mechanism 52 (2)
of action (III)
Schizophreniform psychosis; treatment
with atypical antipsychotic drugs
Antipsychotic drugs 54 (1)
Comparative affinity for different
receptors/transporters
Antipsychotic drugs 55 (1)
Subclasses according to presumed mode of
therapeutic action
Antipsychotic drugs 56 (2)
Comparative side effect profile
Anxiolytics 58 (12)
Drugs effective in anxiety disorders 58 (2)
Potential mechanisms involved in
anxiolytic effects; empirical findings
Benzodiazepines and agents that enhance 60 (2)
γ-aminobutyric acid type A (GABAA)
activity
Supposed mechanism of action
Agents that suppress γ-aminobutyric 62 (2)
acid type A (GABAA) activity
Supposed mechanism of action
Buspirone 64 (2)
Supposed mechainsm of anxiolytic effect
Treatments for OCD (obsessive-compulsive 66 (2)
disorder)
Supposed mechanism of action
Benzodiazepines and other sedative hypnotics 68 (1)
Comparative clinical and side effect
profiles
Benzodiazepines 69 (1)
Metabolism
Selected adrenergic drugs 70 (6)
α2-adrenergic antagonist -- yohimbine 70 (2)
Supposed mechanism of improving erectile
dysfunction
α2-adrenergic agonists -- 72 (2)
clonidine/lofexidine
Therapeutic mechanisms in opioid
withdrawal. Mechanism of adverse side
effects
β-adrenergic antagonists (β 74 (2)
blockers) - pindolol
Supposed mode of accelerating and
augmenting the antidepressant effects of
SSRls
Miscellaneous drugs 76 (6)
Drugs effective for the treatment of 76 (2)
extrapyramidal symptoms (EPS)
Suggested mechanisms that induce EPS and
relevant drug treatments
Drugs effective for the treatment of 78 (1)
extrapyramidal symptoms (EPS)
Comparative profile
Antihistamines 79 (1)
Comparative profile
Drugs studied for the treatment of Dementia 80 (2)
of the Alzheimer type (DAT)
Suggested mechanisms involved in DAT and
potential drug treatments
Drugs affecting sexual functioning 82 (14)
Male sexual behavior 82 (2)
Suggested modulators
Erection 84 (2)
Supposed mechanism and various agents
that can induce erection
Ejaculation 86 (2)
Supposed mechanism and various agents
that can affect retrograde ejaculation
Phenothiazine's-induced retrograde 88 (2)
ejaculation
Suggested mechanism of
phenothiazine's-induced retrograde
ejaculation and treatment options
Female sexual behavior 90 (2)
Suggested modulators
Sexual dysfunctions (I) 92 (2)
Antidepressants-induced sexual
dysfunctions
Sexual dysfunctions (II 94 (2)
Antipsychotics-induced sexual dysfunctions
Other biological treatments 96 (5)
Electroconvulsive therapy (ECT) 96 (2)
Supposed mechanism or action
Light therapy 98 (3)
Supposed mechanism or action in major
depressive disorder with seasonal pattern
Section B Abused substances 101(24)
Commonly abused substances -- general 102(4)
comparisons
Abused substances 102(1)
Direct effects as first messengers
Abused substances -- acute effects 103(1)
Frequently encountered non-psychiatric
symptoms
Abused substances -- acute effects 104(1)
Frequently encountered psychiatric
symptoms
Abused substances 105(1)
Frequently encountered withdrawal symptoms
Commonly abused substances -- specific 106(19)
profiles
Abused substances -- opioids 106(2)
Supposed mechanism of dependence,
withdrawal symptoms and treatment options
Abused substances -- amphetamines 108(2)
Supposed mechanism of dependence, adverse
effects and treatment options
Abused substances -- cocaine 110(2)
Supposed mechanism of dependence, adverse
effects and treatment options
Abused substances -- phencyclidine (PCP) 112(2)
Supposed mechanism of dependence, adverse
effects and treatment options
Abused substances -- alcohol 114(2)
Abnormal findings in acute intoxication
and withdrawal. Treatment options
Abused substances -- cannabis 116(2)
Supposed mechanism of dependence and
adverse effects
Abused substances -- hallucinogens 118(2)
(lysergic acid diethylamide)
Supposed mechanism of action and
treatment options
Abused substances -- benzodiazepines 120(2)
Supposed mechanism or dependence,
withdrawal, symptoms and treatment options
Abused substances -- nicotine 122(3)
Supposed mechanism of dependence,
withdrawal symptoms and treatment options
Section C Drug interactions 125(28)
Antidepressants, mood stabilizers and 126(16)
monoamine oxidase inhibitors
Tricyclic and tetracyclic antidepressants 126(2)
Major drug interactions
Selective serotonin reuptake inhibitors 128(2)
(SSRls) -- fluoxetine
Major drug interactions
Selective serotonin reuptake inhibitors 130(2)
(SSRls) -- fluvoxamine and paroxetine
Major drug interactions
Selective serotonin reuptake inhibitors 132(2)
(SSRls) -- sertraline and citalopram
Major drug interactions
Mood stabilizers -- lithium 134(2)
Major drug interactions
Mood stabilizers -- carbamazepine and 136(2)
valproate
Major drug interactions
Monoamine oxidase inhibitors (MAOIs) 138(2)
Major drug interactions
Reversible inhibitors of monoamine oxidase 140(2)
type A (RIMAs) -- moclobemide
Major drug interactions
Antipsychotics 142(6)
Typical antipsychotics -- phenothiazines 142(2)
Major drug interactions
Typical antipsychotics -- haloperidol and 144(2)
miscellaneous drugs
Major drug interactions
Atypical antipsychotics -- clozapine, 146(2)
olanzapine, risperidone and sertindole
Major drug interactions
Anxiolytics and alcohol 148(5)
Benzodiazepines and buspirone 148(2)
Major drug interactions
Alcohol (ethanol) 150(3)
Major drug interactions
Section D Treatment strategies 153(68)
Mood disorders 154(20)
Major depressive disorder (non-resistant) 154(2)
Treatment strategies
Major depressive disorder with psychotic 156(2)
features
Treatment strategies
Treatment-resistant depression (TRD) 158(2)
Treatment strategies
Major depressive disorder with atypical 160(2)
features
Treatment strategies
Dysthymic disorder 162(2)
Treatment strategies
Unipolar disorder -- maintenance treatment 164(1)
Treatment strategies
Major depressive disorder with seasonal 165(1)
patterns
Treatment strategies
Major depressive episode as part of bipolar 166(2)
I disorder
Treatment strategies
Acute manic episode 168(2)
Treatment strategies
Bipolar I disorder with rapid cycling 170(2)
Treatment strategies
Bipolar disorder -- maintenance treatment 172(2)
Treatment strategies
Psychotic disorders 174(8)
Acute exacerbation of schizophrenia 174(2)
Treatment strategies
Schizoaffective disorder -- depressive 176(2)
episode
Treatment strategies
Schizoaffective disorder -- manic episode 178(2)
Treatment strategies
Delusional disorder 180(2)
Treatment strategies
Anxiety disorders 182(10)
Panic disorder 182(2)
Treatment strategies
Simple phobia 184(1)
Treatment strategies
Social phobia 184(2)
Treatment strategies
Generalized anxiety disorder (GAD) 186(2)
Treatment strategies
Obsessive-compulsive disorder (OCD) 188(2)
Treatment strategies
Posttraumatic stress disorder (PTSD) 190(2)
Treatment strategies
Selected personality disorders 192(14)
Paranoid personality disorder 192(2)
Treatment strategies
Schizoid personality disorder 194(2)
Treatment strategies
Schizotypical personality disorder 196(2)
Treatment strategies
Borderline personality disorder 198(2)
Treatment strategies
Histrionic personality disorder 200(2)
Treatment strategies
Avoidant personality disorder 202(2)
Treatment strategies
Obsessive-compulsive personality disorder 204(2)
Treatment strategies
Eating disorders 206(4)
Anorexia nervosa 206(2)
Treatment strategies
Bulimia nervosa 208(2)
Treatment strategies
Attention deficit hyperactivity disorder 210(2)
(ADHD) -- adult type
Attention deficit hyperactivity disorder 210(2)
(ADHD) -- adult type
Treatment strategies
Disorders associated with iatrogenic causes 212(9)
Neuroleptic malignant syndrome 212(2)
Treatment strategies
Tardive dyskinesia (TD) 214(2)
Treatment strategies
Akathisia 216(2)
Treatment strategies
Delirium 218(3)
Treatment strategies
Section E Bibliography 221